Evolus, Inc.
EOLSNasdaq
$5.73
↑ +1.8%Jul 17 close · end-of-day
Price
1Y↓ -37.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$373.5M
Enterprise Value
$480.1M
P/E
—
P/S
1.2
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-10.7%
Dividend Yield
—
Revenue (TTM)
$301.8M
Net Income (TTM)
-$43.4M
Free Cash Flow (TTM)
-$40.1M
Gross Margin
66.1%
Operating Margin
-8.1%
Net Margin
-14.4%
ROE
150.9%
ROIC
-24.7%
Debt / Equity
-5.4
Net Cash
-$106.6M
Return 1Y
-38.6%
Company profile
Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. Jeuveau is a proprietary 900 kilodalton purified botulinum toxin type A formulation for the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
- CEO
- David Moatazedi
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 170
- Headquarters
- California
- Website
- evolus.com
Management & directors
- Avelar RuiSee Remarks
- Moatazedi DavidSee Remarks
- Mitchell TatjanaChief Financial Officer
- Yamagishi-Dressler TomokoChief Marketing Officer
Roles derived from SEC Form 4 filings.
Earnings
EOLS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$73.1M↑ +6.7%
Diluted EPS-$0.16↓ -46.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $56.5M | $99.7M | $148.6M | $202.1M | $266.3M | $297.2M |
| Gross profit | — | — | $89.8M | $137.6M | $182.3M | $197.1M |
| Operating income | -$153.1M | -$44.4M | -$65.3M | -$49.2M | -$34.4M | -$32.7M |
| Net income | -$163.0M | -$46.8M | -$74.4M | -$61.7M | -$50.4M | -$51.6M |
| Diluted EPS | -$4.83 | -$0.94 | -$1.33 | -$1.08 | -$0.81 | -$0.80 |
| Operating cash flow | -$57.9M | -$33.4M | -$84.9M | -$34.0M | -$18.0M | -$42.3M |
| Free cash flow | -$58.7M | -$33.8M | -$86.5M | -$34.5M | -$19.5M | -$45.7M |
| Gross margin | — | — | 60.4% | 68.1% | 68.5% | 66.3% |
| Operating margin | -270.7% | -44.6% | -44.0% | -24.4% | -12.9% | -11.0% |
| Net margin | -288.3% | -47.0% | -50.1% | -30.5% | -18.9% | -17.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $66.9M | $61.1M | $78.9M | $68.5M | $69.4M | $69.0M | $90.3M | $73.1M |
| Gross profit | $47.1M | $42.1M | $52.6M | $46.7M | $45.3M | $45.8M | $59.3M | $48.9M |
| Operating income | -$7.7M | -$15.5M | -$2.3M | -$15.2M | -$10.2M | -$11.5M | $4.2M | -$6.8M |
| Net income | -$11.3M | -$19.2M | -$6.8M | -$18.9M | -$17.1M | -$15.7M | $130,000.00 | -$10.7M |
| Diluted EPS | -$0.18 | -$0.30 | -$0.11 | -$0.30 | -$0.27 | -$0.24 | $0.01 | -$0.16 |
| Operating cash flow | -$6.5M | -$5.7M | $4.8M | -$15.6M | -$24.8M | -$14.7M | $12.8M | -$10.0M |
| Free cash flow | -$6.9M | -$6.0M | $4.4M | -$16.0M | -$25.5M | -$15.6M | $11.3M | -$10.4M |
| Gross margin | 70.3% | 68.9% | 66.7% | 68.1% | 65.3% | 66.5% | 65.7% | 66.9% |
| Operating margin | -11.5% | -25.3% | -2.9% | -22.1% | -14.7% | -16.7% | 4.7% | -9.4% |
| Net margin | -17.0% | -31.4% | -8.6% | -27.6% | -24.7% | -22.8% | 0.1% | -14.6% |
Company news
Jul 10, 2026
May 19, 2026
May 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-20 | MOATAZEDI DAVID· See Remarks | Sale | 13,669 | $4.75 | $64,929.12 | filing |
| 2026-03-20 | Avelar Rui· See Remarks | Sale | 3,119 | $4.75 | $14,815.25 | filing |
| 2026-03-17 | MOATAZEDI DAVID· See Remarks | Sale | 116,720 | $4.89 | $570,562.38 | filing |
| 2026-03-17 | Avelar Rui· See Remarks | Sale | 29,996 | $4.89 | $146,629.45 | filing |
| 2026-03-16 | MOATAZEDI DAVID· See Remarks | Option exercise | 67,489 | $0.00 | $0.00 | filing |
| 2026-03-16 | Avelar Rui· See Remarks | Option exercise | 8,804 | $0.00 | $0.00 | filing |
| 2026-02-17 | Avelar Rui· See Remarks | Award | 94,913 | $0.00 | $0.00 | filing |
| 2026-02-17 | GILL DAVID N | Award | 45,559 | $0.00 | $0.00 | filing |
| 2026-02-17 | MOATAZEDI DAVID· See Remarks | Award | 313,212 | $0.00 | $0.00 | filing |
| 2026-02-17 | Parschauer Karah Herdman | Award | 45,559 | $0.00 | $0.00 | filing |
| 2026-02-17 | Stewart Brady | Award | 45,559 | $0.00 | $0.00 | filing |
| 2026-02-17 | Mitchell Tatjana· Chief Financial Officer | Award | 121,489 | $0.00 | $0.00 | filing |
| 2026-02-17 | White Albert G III | Award | 45,559 | $0.00 | $0.00 | filing |
| 2026-02-17 | Malik Vikram | Award | 45,559 | $0.00 | $0.00 | filing |
| 2025-12-22 | MOATAZEDI DAVID· See Remarks | Sale | 10,539 | $7.15 | $75,361.23 | filing |
| 2025-12-22 | Avelar Rui· See Remarks | Sale | 2,261 | $7.15 | $16,167.73 | filing |
| 2025-09-08 | Mitchell Tatjana· Chief Financial Officer | Award | 104,603 | $0.00 | $0.00 | filing |
| 2025-08-22 | Yamagishi-Dressler Tomoko· Chief Marketing Officer | Sale | 5,722 | $7.51 | $42,972.22 | filing |
| 2025-08-15 | Stewart Brady | Buy | 30,000 | $6.82 | $204,486.00 | filing |
| 2025-06-16 | MOATAZEDI DAVID· See Remarks | Sale | 16,582 | $9.89 | $164,054.02 | filing |
Latest 20 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.